For those patients who have not had TTF previously (we do not offer it in the salvage setting if they had received it initially), we evaluate for clinical trial eligibility first, and offer this option (unless for clinical reasons resection is urgently indicated). If a ...

Most patients with recurrent glioblastoma are enrolled in clinical trials that often do not permit use of TTFields. The EF-11 trial of recurrent glioblastoma did not demonstrate a survival benefit. Nevertheless, based on that trial, TTFields is a good option for recurrent disease, at least as good a...

This really depends. Some patients may have already tried second line agents including bevacizumab and/or systemic therapy. Some patients who have declined TTF upfront may change their minds if they were to progress on second line therapy. I would follow the TTF trial for re...